Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Fennec Pharmaceuticals (FENC) Non-cash Items (2018 - 2025)

Fennec Pharmaceuticals filings provide 5 years of Non-cash Items readings, the most recent being $4.2 million for Q4 2025.

On a quarterly basis, Non-cash Items fell 15.88% to $4.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.2 million, a 15.88% decrease, with the full-year FY2025 number at $4.2 million, down 15.88% from a year prior.
Non-cash Items hit $4.2 million in Q4 2025 for Fennec Pharmaceuticals, down from $5.0 million in the prior quarter.
In the past five years, Non-cash Items ranged from a high of $5.0 million in Q4 2024 to a low of $4.2 million in Q4 2025.